NEW YORK (GenomeWeb) – Genomic Health reported after the close of the market Wednesday that its first quarter revenues were up 19 percent percent year over year, driven primarily by continued growth in test volume, mainly in breast cancer, but also in prostate cancer.

The Redwood City, California-based molecular diagnostics firm brought in total revenues of $80.9 million for the three months ended March 31, up from $68.2 million in the first quarter of 2015, and beating the consensus Wall Street estimate of $78.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.